近期发布 | Pharma Intelligence

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

By Aidan Fry 27 Nov 2020

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Scrip

Stockwatch: The First Coronavirus Earnings Season May Come Early

08 Apr 2020

The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.

Scrip

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

By Andy Smith 30 Jan 2020

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

Datamonitor Healthcare

Allergan uses Native American tribe’s sovereign immunity to delay generic entry

By Zara Fulton 07 Oct 2017

Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.

Datamonitor Healthcare

Gilead expands into CAR-T therapy with $11.9bn purchase of Kite Pharmaceuticals

By Oliver Spray 07 Oct 2017

Pharmavitae Analytics expects Gilead’s purchase of Kite to generate long-term growth for Gilead.

Datamonitor Healthcare

Xtandi will have first-mover advantage in non-metastatic prostate cancer setting

By Edward Thomason 07 Oct 2017

Positive results from the Phase III PROSPER trial (ClinicalTrials.gov identifier

Datamonitor Healthcare

Alnylam and partner Sanofi deliver on their RNAi promise with groundbreaking results in rare polyneuropathy condition

By Zara Fulton 07 Oct 2017

Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.

Datamonitor Healthcare

Ocrevus FDA approval marks watershed moment for MS market

02 Apr 2017

Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).